key: cord-0252233-cl6yk1s0 authors: Fakharian, Atefeh; Ebrahimibagha, Hamed; Mirenayat, Maryam Sadaat; Farahmandi, Fargol title: COVID-19 Reinfection in a Patient with Hodgkin Lymphoma: a Case Report date: 2021-01-03 journal: Tanaffos DOI: nan sha: ebc1cfd6b3211bdf78c0c28c826f42cd14c780ef doc_id: 252233 cord_uid: cl6yk1s0 COVID-19 pneumonia has invaded the world and continues to expand. The current evidence of the immune system reaction to this viral pneumonia shows that the post-infectious immunity against the virus may be temporary, and the virus may reinfect the patients after healing from the previous one. Here is presented a 55-year-old female patient, as a known case of Hodgkin lymphoma, diagnosed with COVID-19 reinfection during 40 days. Such evidence may be helpful in further understanding the immunology of the disease. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that can cause coronavirus disease 2019 was first found in Wuhan, China, and rapidly spread throughout the world. COVID-19 is a viral pneumonia with different manifestations that may be mild, severe, or even lethal. Each patient with an underlying disease is affected in some way by COVID-19 (1) . Although the durability of neutralizing antibodies against SARS-CoV-2 is not defined yet, the resistance period is estimated up to 40 days since the onset of symptoms (2) . Evidence of antibody response to SARS-CoV-2 and similar coronaviruses is limited; however, an animal model study shows at least a temporary immunity after recovery from COVID-19 against reinfection (3) . Some other evidence shows that the result of RT-PCR becomes positive again in some patients within 10-28 days after recovery, which even reaches 37 days in some cases (4) (5) (6) . It is known that cancers and therapies of patients' blood affect the immune system. Hence, patients, especially the ones with such cancer, are at a higher risk for SARS-CoV-2 infection or reinfection (13, 14) . Normally, a patient is not expected to develop reinfection when a short interval elapsed since resolution from the disease. The current report presents a patient, as a known case of Hodgkin lymphoma (HL), who experienced two confirmed SARS-Cov-2 infections in a short period. The patient was a 55-year-old female, as a known case of Hodgkin lymphoma, from 1.5 years ago and her last chemotherapy was 55 days before attending the center. In two reports, patients who had a positive throat swab after discharge had stable or improved symptoms on radiographic examination (12, 17) . There is no evidence that patients with a history of the disease and resolved signs and symptoms may transmit it; however, transmission from immunosuppressed patients with a history of the disease is not impossible (3). For a better understanding of the pathophysiology of COVID-19 reinfection, studies should be focused on viral strain genetics, evaluation of immune system response to infection, and inflammatory targets (18) . As discussed earlier, the duration of the immune response plays a significant role in reinfection. Barthold and Smith , in a study on mice, showed that despite similar antibody responses, there are mechanisms affecting the immune system resistance against murine coronavirus species (19) . From the evidence and observations concerning the immune response to COVID-19 and SARS, it can be concluded that the humoral immunologic response is not enough to make the long-term immunity, and the cellular immunity and related cytokines play pivotal roles in a long-standing immunity (20, 21) . It is recommended that reducing the dose of chemotherapy should be considered in patients receiving immunochemotherapy in COVID-19 epidemic areas. In addition, the effect of immunotherapy with monoclonal antibodies-e g, rituximab, on COVID-19 should also be considered (22) . Based on the mentioned evidence, it is strongly believed that the presented patient was reinfected with SARS-CoV-2 just 40 days after recovery from the previous one. Since the patient had Hodgkin lymphoma, it can be assumed that the effect of chemoradiotherapy on her immune system may affect the active immunity expected to be acquired after the first infection; therefore, after another exposure, she was reinfected with the virus. The experience of this case and similar reported cases show that unlike most viral infections, COVID-19 can cause reinfection even as short as 40 days after recovery from the previous one. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19 Polymerase Chain Reaction Assays Reverted to Positive in 25 Discharged Patients With COVID-19 False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence Virus Returning Eleven faces of coronavirus disease 2019 COVID-19 infection: the perspectives on immune responses Postdischarge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China Risk of COVID-19 for patients with cancer COVID-19 in persons with haematological cancers Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19 Efficacy of Serology Testing in Predicting Reinfection in Patients With SARS-CoV-2 Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound? Duration of challenge immunity to coronavirus JHM in mice Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection Molecular Basis of Coronavirus Virulence and Vaccine Development A Primary Mediastinal Large B-Cell Lymphoma Patient with COVID-19 Infection after Intensive Immunochemotherapy: A Case Report